Close

Overview of CD19-targeted CAR Cell Therapies

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs is a contract research organization (CRO) formed and managed by a team of scientists and specialists with considerable expertise and experience in cell therapy research and development. We are committed to offering superior products and services to clients in the academic and industrial sectors across the world, supporting the pursuit of breakthrough scientific discoveries that successfully enhance preclinical and clinical research.

Background of CD19

B-lymphocyte antigen CD19, also known as CD19 molecule (cluster of differentiation 19), B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12 and CVID3, is a 95 kDa type I transmembrane glycoprotein belonging to the immunoglobulin (Ig) superfamily (IgSF), with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. The CD19 protein is encoded by the CD19 gene located on the short arm of 16p11.2 on chromosome 16. The gene consists of 15 exons, 4 encoding extracellular domains and 9 encoding cytoplasmic domains. The CD19 molecule contains 240 amino acid residues. The signal peptide is composed of the first 19 amino acids. It has two C2-type Ig-like extracellular domains composed of 20–294 amino acids. The first Ig-like ring is crucial for the correct 3D folding of CD19 and its final transport to the plasma membrane.

Structure of CD19Fig.1 Structure of CD19

CD19 Signaling Pathways

CD19 is a key component in the B cell receptor (BCR) signaling pathway. B cells express CD19 along with other proteins, including the BCR, on their surface. When an antigen binds to the BCR, it triggers a cascade of signals that activate the B cell and lead to the production of antibodies. In mature B cells, CD19 serves as a co-receptor in this process and helps to amplify the signal from the BCR. When the BCR binds to an antigen, CD19 is brought into close proximity with other signaling molecules and facilitates the activation of these molecules. This results in the activation of multiple downstream signaling pathways that eventually lead to the activation of the B cell and the production of antibodies. In this way, CD19 plays an important role in the immune response by helping to ensure that the B cell response is appropriately activated in response to antigens.

In developing B cells, however, CD19 may play a different role in regulating BCR signaling. In some cases, the differential regulation of BCR signaling by CD19 can become dysregulated in B-cell lymphoid malignancies, leading to the development of cancer. For example, in some cases of acute lymphoblastic leukemia (ALL), the cancer cells have a high affinity for BCR, leading to constitutive activation of BCR signaling and uncontrolled growth. In these cases, targeting CD19 can help disrupt the BCR signaling pathway and slow or halt the growth of the cancer cells. One approach is to use chimeric antigen receptor T cell (CAR-T) therapy, which involves genetically modifying a patient's own T cells to express a receptor that recognizes and binds to CD19. These modified T cells are then infused back into the patient, where they can specifically target and kill the cancer cells that express CD19.

Clinic Status of CD19-Targeted CAR Cell Therapies

Clinical trials of CD19-targeted CAR cell therapy have shown promising results, with response rates ranging from 50 to 90% in patients with relapsed or refractory B cell malignancies. The approval of CD19-targeted CAR-T cell therapies has revolutionized the treatment landscape for B cell malignancies, providing new hope for patients with these diseases who have exhausted conventional treatment options. As far, four CD19-targeted CAR-T cell products have been approved by the FDA for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). These products are made from autologous cells derived from the patient by leukapheresis and contain a CAR targeting CD19. The CAR transgene is transduced into cells using a replication-incompetent retrovirus (axicabtagene and brexucabtagene) or lentivirus (all others) and contains a costimulatory molecule (CD28 for axicabtagene and brexucabtagene; CD137, also known as 4-1BB, for all others).

Table 1. Approved CD19-Targeted CAR Cell Therapies

Brand Name Generic Name Manufacturer Indication Date of FDA Approval
Kymriah Tisagenlecleucel Novartis Pediatric and young adult (age≤25) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) August 30, 2017
Adult R/R diffuse large B-cell lymphoma (DLBCL) May 1, 2018
Yescarta Axicabtagene ciloleucel Kite Pharma R/R DLBCL, primary mediastinal B-cell lymphoma (PMBCL), high- grade B-cell lymphoma, transformed follicular lymphoma (FL) October 18, 2017
R/R FL March 5, 2021
Tecartus Brexucabtagene autoleucel Kite Pharma Mantle cell lymphoma July 24, 2020
Adult R/R B-cell ALL October 1, 2021
Breyanzi Lisocabtagene maraleuecel Juno Therapeutics R/R large B-cell lymphoma February 5, 2021

As far, ongoing CD19-targeted CAR therapy clinical trials are mainly focused on non-Hodgkin lymphoma (NHL), diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). Some of the key areas of focus in these trials include combination therapy, off-the-shelf CAR-T cells, next-generation CAR designs, and maintenance therapy. Over half of these ongoing clinical trials are in Phase I, and only a few have made it to Phase III or Phase II/III status. Among these CD19-targeted CAR cell therapy trials, a few are designed to target two targets, CD19 and B cell maturation antigen (BCMA), and focus on CD19/BCMA-expressing autoimmune diseases, such as immune nephritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, POEMS syndrome, and amyloidosis.

Table 2. Ongoing CD19 -Targeted CAR Cell Therapy Clinical Trials

NCT Number Title Conditions Sponsor/Collaborators Phases
NCT05673447 The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma Changhai Hospital|Nanjing Enricnk Biotech Co., Ltd Early Phase 1
NCT05453669 Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL B-cell Non-Hodgkin's Lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University|Zhejiang Ruijiamei Biotechnologies, Co., Ltd. Phase 1
NCT04661020 CD19 CAR-T Therapy for Elderly Patients With B-cell Non-Hodgkin's Lymphoma Non-hodgkin Lymphoma,B Cell Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT04532281 A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies Acute Lymphoblastic Leukemia|Non-Hodgkin Lymphoma of Soft Tissue Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT04532268 A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL Acute Lymphoblastic Leukemia|Non-hodgkin Lymphoma,B Cell Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT05715606 Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research Diffuse Large B-cell Lymphoma Anhui Provincial Hospital|Leman Biotech Co., Ltd Early Phase 1
NCT05210907 Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia B-cell Acute Lymphoblastic Leukemia Seoul National University Hospital Phase 1
NCT05470777 CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL B-cell Acute Lymphoblastic Leukemia The First Affiliated Hospital of Soochow University|National Natural Science Foundation of China(Grant No. 81970138)|Jiangsu Province Natural Science Foundation of China (Grant No. BK20210091)|Jining Medical University|The Second People's Hospital of Huai'an|First Affiliated Hospital Bengbu Medical College|Northern Jiangsu Province People's Hospital|Affiliated Hospital of Nantong University|Suzhou Hospital of Traditional Chinese Medicine Phase 1|Phase 2
NCT04684472 Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Leukemia Liqun Zou|Sichuan University Phase 1
NCT04639739 Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. NHL Xinqiao Hospital of Chongqing|Chongqing Precision Biotech Co., Ltd Early Phase 1
NCT05432635 Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Transformed Non-Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT05164042 Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Relapse Leukemia|Refractory Leukemia Shenzhen University General Hospital Phase 1|Phase 2
NCT03984968 CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, Adult B-Cell The First Affiliated Hospital of Soochow University Phase 1|Phase 2
NCT04289220 Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia Yan'an Affiliated Hospital of Kunming Medical University Phase 1
NCT04443829 Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma Primary CNS Lymphoma University College, London Phase 1
NCT03937544 Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL Relapsed B Acute Lymphoblastic Leukaemia|Refractory B Acute Lymphoblastic Leukaemia National University of Malaysia|Gaia Science Phase 2|Phase 3
NCT05436223 Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma B-cell Non-Hodgkin's Lymphoma Hrain Biotechnology Co., Ltd.|Shanghai Zhongshan Hospital Phase 2
NCT04787263 CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma Bambino Gesù Hospital and Research Institute Phase 1|Phase 2
NCT03275493 Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia|CD19 Positive|Relapse|Refractory Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University Phase 1|Phase 2
NCT05333302 Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma B-cell Acute Lymphoblastic Leukemia|Lymphoblastic B-Cell Lymphoma Belarusian Research Center for Pediatric Oncology, Hematology and Immunology Phase 1
NCT04484012 Modified Immune Cells (CD19 CAR-T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) Phase 2
NCT04271410 CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma Leukemia|Lymphoma, Large B-Cell, Diffuse|Leukemia, B-cell|Lymphoma, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell Chongqing Precision Biotech Co., Ltd Phase 1|Phase 2
NCT04271800 Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma Leukemia|Lymphoma|Leukemia, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell Chongqing Precision Biotech Co., Ltd Phase 1|Phase 2
NCT04653493 CD19 Targeted CAR-T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)|Refractory B Cell Acute Lymphoblastic Leukemia (ALL) Sabz Biomedicals|Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran|Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran Phase 1
NCT05326243 Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T) for Relapsed or Refractory B-cell Lymphoma Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Large B-cell Lymphoma|Follicular Lymphoma Grade 3A|Follicular Lymphoma Grade 3B Pell Bio-Med Technology Co., Ltd. Phase 1|Phase 2
NCT04100187 Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia Leukemia Kecellitics Biotech Company Ltd|Hebei Yanda Ludaopei Hospital Phase 1
NCT04381741 CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma Diffuse Large B-cell Lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1
NCT05707273 CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission B Acute Lymphoblastic Leukemia City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT02546739 Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL Leukemia|Lymphoma Beijing Doing Biomedical Co., Ltd.|The First Hospital of Jilin University|Hebei Yanda Ludaopei Hospital Phase 1
NCT05176275 PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells Lymphoma The First Affiliated Hospital of Soochow University Not Applicable
NCT03774654 CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) Refractory B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Small Lymphocytic Lymphoma|Relapsed Adult ALL|Relapsed CLL|Relapsed Non Hodgkin Lymphoma Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute Phase 1
NCT03373071 Anti-CD19 CAR-T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL CD19-ALL|CD19-LNH Bambino Gesù Hospital and Research Institute Phase 1|Phase 2
NCT05143112 Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma Non-hodgkin Lymphoma,B Cell Shenzhen University General Hospital Phase 1|Phase 2
NCT05625594 Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma Central Nervous System Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT05679687 ThisCART19A Bridging to alloHSCT for R/R B-ALL CAR|Refractory Acute Lymphoblastic Leukemia|Relapsed Adult ALL The First Affiliated Hospital of Soochow University|Fundamenta Therapeutics, Ltd. Phase 1
NCT04795882 A New Study Evaluating the Activity of Modular CAR-T for mYeloma Multiple Myeloma University College, London Phase 1
NCT05613348 CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma B-cell Acute Lymphoblastic Leukemia|B-Cell Lymphoma, Unspecified Zhujiang Hospital|Guangdong Zhaotai Cell Bio-tech Co., LTD Phase 1|Phase 2
NCT05645601 CAR-NK Targeted CD19 for r/r B-cell Malignancies Adult Relapsed/Refractory B-cell Hematologic Malignancies Affiliated Hospital to Academy of Military Medical Sciences|Beijing JD Biotech Co. LTD. Phase 1
NCT00586391 CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL B Cell Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine Phase 1
NCT05659628 CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL Diffuse Large B-cell Lymphoma Ningbo No. 1 Hospital|Zhejiang University Phase 1
NCT04796675 Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non Hodgkin's Lymphoma Wuhan Union Hospital, China|Shanghai Simnova Biotechnology Co.,Ltd. Phase 1
NCT05410041 Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non Hodgkin Lymphoma Beijing Boren Hospital Phase 1
NCT05020392 Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Burkitt Lymphoma Wuhan Union Hospital, China|Wuhan Si'an Medical Technology Co., Ltd Phase 3
NCT05665062 Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies CLL/SLL|NHL|Mantle Cell Lymphoma|Follicular Lymphoma|Large B-cell Lymphoma|Indolent B-Cell Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma Synthekine Phase 1
NCT01815749 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma Adult Grade III Lymphomatoid Granulomatosis|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrm Macroglobulinemia City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT05554939 Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL Non Hodgkin's Lymphoma Chinese PLA General Hospital Phase 1|Phase 2
NCT05269914 Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL Diffuse Large B Cell Lymphoma The Affiliated Hospital of Qingdao University Not Applicable
NCT04637763 CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma Lymphoma, Non-Hodgkin|Relapsed Non Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Non Hodgkin Lymphoma|Lymphoma|B Cell Lymphoma|B Cell Non-Hodgkin's Lymphoma Caribou Biosciences, Inc. Phase 1
NCT03720457 Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. CD19-positive|Diffuse Large B-cell Lymphoma|Follicular Lymphoma Hrain Biotechnology Co., Ltd.|Shanghai Zhongshan Hospital Phase 1
NCT05472558 Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL B-cell Non Hodgkin Lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1
NCT01087294 Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1
NCT03064269 CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia B-cell Acute Lymphocytic Leukemia Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University Phase 1
NCT05239676 Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma Lymphoma Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT04881240 Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory|Pediatric ALL St. Jude Children's Research Hospital Phase 1
NCT04887012 Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL B-cell Non Hodgkin Lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1
NCT01683279 A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia B Cell Leukemia Seattle Children's Hospital Phase 1
NCT05487651 Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies NHL, Relapsed, Adult|B-cell Lymphoma|B-cell Leukemia|DLBCL - Diffuse Large B Cell Lymphoma|ALL, Adult B Cell|ALL, Childhood|CLL/SLL Athenex, Inc. Phase 1
NCT05381662 CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment Acute Lymphoblastic Leukemia in Remission Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University Phase 1|Phase 2
NCT05585996 Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma Relapsed and Refractory B-cell Lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1
NCT04943016 CD19 CAR-T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies Relapsed/Refractory B-Cell Malignancies National Taiwan University Hospital Phase 1
NCT02050347 Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) Non-Hodgkin's Lymphoma|B-Cell ALL|B-Cell CLL Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute Phase 1
NCT04649112 Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies CD19 Expressing Malignancies|Hematologic Malignancy Precision BioSciences, Inc. Phase 1
NCT05674175 Co-administration of CART22-65s and huCART19 for B-ALL B-cell Acute Lymphoblastic Leukemia|B Lineage Lymphoblastic Lymphoma Stephan Grupp MD PhD|University of Pennsylvania|Children's Hospital of Philadelphia Phase 1|Phase 2
NCT02028455 A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia CD19+ Acute Leukemia Seattle Children's Hospital Phase 1|Phase 2
NCT04325841 Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Acute Lymphoblastic Leukemia, Pediatric|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia Beijing Boren Hospital Phase 2
NCT03676504 Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Acute Lymphoblastic Leukemia, Adult|Acute Lymphoblastic Leukemia, Pediatric|Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma University Hospital Heidelberg Phase 1|Phase 2
NCT01853631 Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute Phase 1
NCT05648019 CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Lymphoblastic Leukemia|Lymphoblastic Leukemia in Children|Lymphoblastic Leukemia, Acute Adult|B-cell Acute Lymphoblastic Leukemia|Large B-cell Lymphoma|CAR KK Women's and Children's Hospital|Singapore General Hospital Phase 2
NCT04732845 Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia Benjamin Tomlinson|Case Comprehensive Cancer Center Phase 1
NCT05385263 Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion B Cell Lymphoma Tel-Aviv Sourasky Medical Center Phase 2
NCT04544592 UCD19 CAR-T in Treatment of Pediatric B-ALL and B-NHL B-cell Acute Lymphoblastic Leukemia|B-cell Non Hodgkin Lymphoma University of Colorado, Denver|National Cancer Institute (NCI) Phase 1|Phase 2
NCT02146924 Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT05574114 A Study of Radiation Therapy Before CAR-T Cell Therapy for People With B Cell Lymphoma Non-Hodgkin Lymphoma|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory Memorial Sloan Kettering Cancer Center Phase 1
NCT02935257 Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 Leukemia, Lymphoblastic, Acute, Lymphoma University College, London Phase 1
NCT03765177 CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia Ottawa Hospital Research Institute Phase 1|Phase 2
NCT02051257 Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT05052528 Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma Mehrdad Abedi, MD|National Cancer Institute (NCI)|University of California, Davis Phase 1
NCT03666000 Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Non-Hodgkin Lymphoma|B-cell Acute Lymphoblastic Leukemia Precision BioSciences, Inc. Phase 1|Phase 2
NCT00840853 Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT Acute Lymphoblastic Leukemia (ALL)|Chronic Lymphocytic Leukemia (CLL)|Non Hodgkin's Lymphoma Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine Phase 1
NCT05665725 Siltuximab for the Prevention of CAR-T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma Timothy Voorhees|Ohio State University Comprehensive Cancer Center Phase 1
NCT03696784 Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Lymphoma|Lymphoma, B-Cell|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Bellicum Pharmaceuticals|The V Foundation Phase 1
NCT05702853 Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL B-cell Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia Medical University of South Carolina Phase 1|Phase 2
NCT05081479 A Study of N-Acetylcysteine (N-AC)in People Receiving CAR T-cell Therapy for Lymphoma Lymphoma Memorial Sloan Kettering Cancer Center Phase 1
NCT04850560 Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma Objective Response Rate Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1
NCT04792593 Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia B-ALL Hebei Senlang Biotechnology Inc., Ltd. Not Applicable
NCT04796441 Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation AML Hebei Senlang Biotechnology Inc., Ltd. Not Applicable
NCT04257578 Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma University of Washington|AstraZeneca Phase 1|Phase 2
NCT05440409 CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL Leukemia, Acute Lymphoblastic|Lymphoblastic Leukemia, Acute, Childhood National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) undefined
NCT00709033 T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute Phase 1
NCT05633615 Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Diffuse Large B-Cell Lymphoma|Grade 3b Follicular Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Transformed Follic Lymph to Diff Large B-Cell Lymphoma|Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma Southwest Oncology Group|National Cancer Institute (NCI)|Genentech, Inc. Phase 2
NCT04640909 Impact of Treatment With Targeted Therapies on the Generation of CAR-T Cells in CLL Patients CLL|Chronic Lymphocytic Leukemia Gruppo Italiano Malattie EMatologiche dell'Adulto Not Applicable
NCT03103971 huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory B Acute Lymphoblastic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Fred Hutchinson Cancer Center|Juno Therapeutics, Inc. Phase 1
NCT05334823 A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Acute Lymphoblastic Leukemia|Relapsed Pediatric ALL|Refractory Acute Lymphoblastic Leukemia Chongqing Precision Biotech Co., Ltd Phase 2
NCT04888442 Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia Chongqing Precision Biotech Co., Ltd Phase 1
NCT05675982 Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells Diffuse Large B Cell Lymphoma Centre Henri Becquerel Not Applicable
NCT04049513 ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) Lymphomas Non-Hodgkin's B-Cell|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL) Malaghan Institute of Medical Research|Wellington Zhaotai Therapies Limited (WZTL) Phase 1
NCT05260957 CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Refractory Non-Hodgkin Lymphoma|Relapsed Non Hodgkin Lymphoma|Aggressive Non-Hodgkin Lymphoma Lazaros Lekakis|Genentech, Inc.|University of Miami Phase 2
NCT03798509 Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia CD19-positive|Acute Lymphoblastic Leukemia Hrain Biotechnology Co., Ltd.|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Phase 1
NCT04608487 Axi-cel in CNS Lymphoma Lymphoma|Lymphoma Cns Dana-Farber Cancer Institute|Kite, A Gilead Company Phase 1
NCT04690192 CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma Large B-cell Lymphoma Zou Dehui|Juventas Cell Therapy Ltd.|Institute of Hematology & Blood Diseases Hospital Phase 1|Phase 2
NCT04545762 Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma|Burkitt Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Diffuse Large B Cell Lymphoma|Small Lymphocytic Lymphoma|Transformed Lymphoma C. Babis Andreadis|University of California, Davis|University of California, San Francisco Phase 1
NCT04892277 CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia Mayo Clinic Phase 1
NCT03155191 Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia Lymphoblastic Leukemia, Acute Adult Takara Bio Inc. Phase 1|Phase 2
NCT05691153 ThisCART19A for B-NHL Relapsed After Auto-CAR T CAR|B Cell Lymphoma|Relapsed Non-Hodgkin Lymphoma The First Affiliated Hospital of Soochow University|Fundamenta Therapeutics, Ltd. Phase 1
NCT03618381 EGFR806 CAR-T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma Seattle Children's Hospital Phase 1
NCT03853616 MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) Acute Lymphoblastic Leukemia Recurrent|B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory|Chronic Lymphocytic Leukemia Recurrent|Chronic Lymphocytic Leukemia Refractory Miltenyi Biomedicine GmbH Phase 1|Phase 2
NCT04880434 Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) Relapsed/Refractory Mantle Cell Lymphoma Kite, A Gilead Company|Gilead Sciences Phase 2
NCT03455972 Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT Safety and Efficacy The First Affiliated Hospital of Soochow University Phase 1|Phase 2
NCT02601313 Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma Relapsed/Refractory Mantle Cell Lymphoma Kite, A Gilead Company|Gilead Sciences Phase 2
NCT03186118 Pilot Study of T-APCs Following CAR-T Cell Immunotherapy for CD19+ Leukemia CD 19+ Acute Leukemia Seattle Children's Hospital Phase 1
NCT04303247 CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent Xinqiao Hospital of Chongqing|Gracell Biotechnology Shanghai Co., Ltd.|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|The Affiliated Hospital Of Guizhou Medical University|Tang-Du Hospital|The General Hospital of Western Theater Command|Chongqing University Cancer Hospital Early Phase 1
NCT01318317 Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) Phase 1|Phase 2
NCT04638270 Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL Lymphoma, Non-Hodgkin Xinqiao Hospital of Chongqing|Gracell Biotechnology Shanghai Co., Ltd.|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|The Second Affiliated Hospital of Chongqing Medical University|The Affiliated Hospital Of Guizhou Medical University|The Second Affiliated Hospital of Kunming Medical University|Chongqing University Cancer Hospital Early Phase 1
NCT02153580 Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|High Grade B-Cell Lymphoma, Not Otherwise Specified|Post-Transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hairy Cell Leukemia|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT05618041 The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies Acute Lymphoblastic Leukemia|Lymphoma|Multiple Myeloma Hebei Senlang Biotechnology Inc., Ltd. Not Applicable
NCT04257175 CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression Acute Myeloid Leukemia Sheba Medical Center Phase 2|Phase 3
NCT03407859 Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL Therapy Related Leukemia Zhujiang Hospital|Nanfang Hospital of Southern Medical University Early Phase 1
NCT05651191 To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL B-cell Acute Lymphoblastic Leukemia Hrain Biotechnology Co., Ltd.|Second Affiliated Hospital of Nanchang University Early Phase 1
NCT04287309 CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS Hematological Malignancy Zhejiang University undefined
NCT05370547 Chidamide Bridging for CAR-T Therapy Non Hodgkin's Lymphoma Chinese PLA General Hospital Phase 1|Phase 2
NCT05664217 NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma Non-Hodgkin Lymphoma|Relapsed/Refractory Diffuse Large B-cell Lymphoma Nektar Therapeutics Phase 2|Phase 3
NCT04637269 Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma Multiple Myeloma Xinqiao Hospital of Chongqing|Carbiogene Therapeutics Co. Ltd. Early Phase 1
NCT02614066 A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Kite, A Gilead Company|Gilead Sciences Phase 1|Phase 2
NCT05098613 Preliminary Safety and Tolerability of CD19x22 CAR-T Cells in Adolescent and Adult R/R B-NHL Patients Non-Hodgkin Lymphoma University of Colorado, Denver Phase 1
NCT05535673 Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL Zhengzhou University|Fundamenta Therapeutics, Ltd. Phase 1
NCT04703686 Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy Diffuse Large B-Cell Lymphoma Refractory|Refractory Indolent Adult Non-Hodgkin Lymphoma|Refractory Transformed B-cell Non-Hodgkin Lymphoma|Refractory Primary Mediastinal Large B-Cell Cell Lymphoma|Refractory Mantle Cell Lymphoma The Lymphoma Academic Research Organisation Phase 2
NCT05085418 A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis Immune Nephritis|Autoimmune Diseases|Lupus Nephritis Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT05085444 A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Scleroderma|Autoimmune Diseases Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT05085431 A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome Sjogren's Syndrome|Autoimmune Diseases Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT05030779 A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus Systemic Lupus Erythematosus|Autoimmune Diseases Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT05640713 Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Henan Cancer Hospital|Fundamenta Therapeutics, Ltd. Phase 1
NCT05106907 Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma B-cell Malignancy Fundamenta Therapeutics, Ltd.|The Affiliated Hospital of Xuzhou Medical University Phase 1
NCT03761056 Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma B-cell Lymphoma Kite, A Gilead Company|Gilead Sciences Phase 2
NCT04384393 Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies B Cell Malignancy Fundamenta Therapeutics, Ltd.|Anhui Provincial Hospital Phase 1
NCT05667155 Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma B-cell Non Hodgkin Lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1
NCT02349698 A Clinical Research of CAR-T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma Leukemia|Lymphoma Southwest Hospital, China Phase 1|Phase 2
NCT05576181 Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Fundamenta Therapeutics, Ltd.|The First Affiliated Hospital of Zhengzhou University Phase 1
NCT05651100 Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma Lymphoma, B-Cell Kecellitics Biotech Company Ltd|Hebei Yanda Ludaopei Hospital Phase 1|Phase 2
NCT04162353 BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma Multiple Myeloma in Relapse|Refractory Multiple Myeloma|Plasmacytoid; Lymphoma iCell Gene Therapeutics|iCAR Bio Therapeutics Ltd.|Peking University Shenzhen Hospital Phase 1
NCT04788472 Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL B-Cell Acute Lymphoblastic Leukemia, Adult Zhejiang University|Yake Biotechnology Ltd. Phase 1|Phase 2
NCT04740203 Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL B-Cell Acute Lymphoblastic Leukemia, Adult Zhejiang University|Yake Biotechnology Ltd. Phase 1|Phase 2
NCT04626739 CAR-T Cells in Treating Patients With Relapsed or Refractory NHL Refractory Indolent Adult Non-Hodgkin Lymphoma Hebei Senlang Biotechnology Inc., Ltd. Early Phase 1
NCT04531046 Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation B-Cell Lymphoma Refractory|B-cell Lymphoma Recurrent The Lymphoma Academic Research Organisation Phase 2
NCT04626765 CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia Childhood Acute Lymphoblastic Leukemia Hebei Senlang Biotechnology Inc., Ltd.|The Second Hospital of Hebei Medical University Early Phase 1
NCT04626726 Adult B-ALL Treated by CAR-T Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation Adult B Acute Lymphoblastic Leukemia Hebei Senlang Biotechnology Inc., Ltd. Early Phase 1
NCT05400109 Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas Non Hodgkin Lymphoma James Michael Martin|Case Comprehensive Cancer Center Phase 1
NCT02625480 Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia|Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Kite, A Gilead Company|Gilead Sciences Phase 1|Phase 2
NCT04340154 Study of Sequential CAR-T Cell Treating Leukemia Children Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoid Leukemia Beijing Boren Hospital Phase 2
NCT05166070 An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors Solid Tumor The First Affiliated Hospital with Nanjing Medical University|Shanghai IASO Biotechnology Co., Ltd Early Phase 1
NCT05141253 Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors Cancer Tongji Hospital|Shanghai IASO Biotechnology Co., Ltd Early Phase 1
NCT04836507 Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients Relapsed Large B-cell Lymphoma|Refractory Large B-cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|High-grade B-cell Lymphoma|Transformed Follicular Lymphoma (TFL) Curocell Inc. Phase 1|Phase 2
NCT02348216 Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Relapsed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma (TFL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|High Grade B-cell Lymphoma (HGBCL) Kite, A Gilead Company|Gilead Sciences Phase 1|Phase 2
NCT05528887 Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies Relapsed/Refractory Hematological Malignancies|Lymphoma|Myeloma|Leukemia The Affiliated People's Hospital of Ningbo University|UTC Therapeutics Inc. Phase 1
NCT05429905 Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Lymphoblastic Leukemia|Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Leukemia in Children|Lymphoblastic Leukemia, Acute Adult|CAR KK Women's and Children's Hospital|Singapore General Hospital|National University Hospital, Singapore Phase 1|Phase 2
NCT05020015 A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Takeda Phase 2
NCT05371093 Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma Relapsed/Refractory Follicular Lymphoma Kite, A Gilead Company|Gilead Sciences Phase 3
NCT05263817 A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis POEMS Syndrome|Amyloidosis|Autoimmune Hemolytic Anemia|Vasculitis Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT05513612 Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies Acute Myeloid Leukemia (AML)|B-cell Non-Hodgkin's Lymphoma (B-NHL)|Multiple Myeloma (MM)|T-Cell Leukemia/Lymphoma, Adult|B-cell Acute Lymphoblastic Leukemia (B-ALL) Shanghai Pudong Hospital|UTC Therapeutics Inc. Phase 1
NCT03938987 Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) Relapsed Non Hodgkin Lymphoma|Relapsed Adult ALL|Relapsed Pediatric ALL University of Alberta|Alberta Cancer Foundation|Canadian Cancer Trials Group Phase 1|Phase 2
NCT05537766 Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Relapsed/Refractory Waldenstrom Macroglobulinemia|Relapsed/Refractory Richter Transformation|Relapsed/Refractory Burkitt Lymphoma|Relapsed/Refractory Hairy Cell Leukemia Kite, A Gilead Company|Gilead Sciences Phase 2
NCT05359211 NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Grade 3b Follicular Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Grade 3b Follicular Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Center|Nektar Therapeutics Phase 1
NCT04790747 Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions Hematological Malignancies Zhejiang University|Yake Biotechnology Ltd. Phase 1|Phase 2
NCT02659943 T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies Lymphoma, B-Cell|Lymphoma, Non-hodgkins National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1
NCT04488354 Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T Relapsed/Refractory B-cell Lymphomas|Diffuse Large B-Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Chronic Lymphocytic Leukemia (CLL)|Marginal Zone Lymphoma (MZL)|Mantle Cell Lymphoma (MCL)|Small Lymphocytic Lymphoma (SLL)|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Burkitt Lymphoma Calibr, a division of Scripps Research Phase 1
NCT04700319 CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies CAR PersonGen BioTherapeutics (Suzhou) Co., Ltd.|Anhui Provincial Hospital Early Phase 1
NCT05523661 Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients Ph Positive ALL|CAR-T Cell|Dasatinib Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Phase 1
NCT04781634 a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL B-ALL Chongqing Precision Biotech Co., Ltd Phase 1|Phase 2
NCT04782193 a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma B Cell Lymphoma Chongqing Precision Biotech Co., Ltd Phase 1|Phase 2
NCT02443831 CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies Acute Lymphoblastic Leukemia|Burkitt Lymphoma University College, London Phase 1
NCT03330691 A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia Leukemia|Lymphoma Seattle Children's Hospital Phase 1
NCT05507827 Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) Lymphoid Leukemia Crystal Mackall, MD|Orca Biosystems, Inc.|Stanford University Phase 1
NCT03241940 Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia Crystal Mackall, MD|Stanford University Phase 1
NCT04648475 Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma Leukemia, B-cell|Lymphoma, B-Cell Chongqing Precision Biotech Co., Ltd Phase 1|Phase 2
NCT05225831 Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia CD19+ and CD 22+ B-ALL Hebei Senlang Biotechnology Inc., Ltd.|Hebei Yanda Ludaopei Hospital Early Phase 1
NCT03233854 CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive Crystal Mackall, MD|California Institute for Regenerative Medicine (CIRM)|Stanford University Phase 1
NCT05421663 A Study of C-CAR039 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma B Cell Non-Hodgkin's Lymphoma Cellular Biomedicine Group, Inc.|City of Hope Medical Center Phase 1
NCT04450069 CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies Relapsed/Refractory B-cell Lymphomas|Diffuse Large B Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Chronic Lymphocytic Leukemia (CLL)|Marginal Zone Lymphoma (MZL)|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma (SLL)|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Burkitt Lymphoma Calibr, a division of Scripps Research Phase 1
NCT04029038 Modified Immune Cells (CD19-CD22 CAR-T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma CD19 Positive|CD22 Positive|Minimal Residual Disease|Progressive Disease|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) Phase 1|Phase 2
NCT05418088 Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Recurrent Acute Lymphoblastic Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent High Grade B-Cell Lymphoma|Recurrent Indolent Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory B-Cell Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory High Grade B-Cell Lymphoma|Refractory Indolent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia Sumithira Vasu|Ohio State University Comprehensive Cancer Center Phase 1
NCT05270772 CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL CD19+ Relapse/Refractory B-ALL Chinese PLA General Hospital Phase 1
NCT04214886 CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies B-Cell Acute Lymphoblastic Leukemia, Adult|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent Loyola University|Leukemia Research Foundation Phase 1
NCT04603872 CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies Multiple Myeloma in Relapse|Multiple Myeloma, Refractory|Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphocytic Leukaemia Refractory|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory Zhejiang University|Yake Biotechnology Ltd. Early Phase 1
NCT04714593 Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia Acute Lymphocytic Leukemia, B-Cell Shanxi Province Cancer Hospital|Shanghai Ultra-T Immune Therapeutics Co. LTD Phase 1|Phase 2
NCT03919526 Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL MRD-positive|Acute Lymphoblastic Leukemia Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Phase 1
NCT04877080 CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL B-cell Lymphoma 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China Phase 1
NCT04714827 Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma Multiple Myeloma Shanxi Province Cancer Hospital|Shanghai Ultra-T Immune Therapeutics Co. LTD Phase 1|Phase 2
NCT04715217 Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma Lymphoma, B-Cell Shanxi Province Cancer Hospital|Shanghai Ultra-T Immune Therapeutics Co. LTD Phase 1|Phase 2
NCT03879382 Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES POMES Syndrome|Relapsed and Refractory POMES Syndrome Hrain Biotechnology Co., Ltd.|Shanghai Changzheng Hospital Phase 1
NCT04499573 Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL B-ALL Federal Research Institute of Pediatric Hematology, Oncology and Immunology Phase 1|Phase 2
NCT04846439 Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL Platelet Transfusion Refractoriness|Acute Leukemia in Remission The First Affiliated Hospital of Soochow University|The Second People's Hospital of Huai'an|The First Affiliated Hospital with Nanjing Medical University|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Phase 1|Phase 2
NCT03684889 CD19-specific CAR-T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma Leukemia|Lymphoma Seattle Children's Hospital Phase 1
NCT03919240 CAR-T Cell Therapy Targeting to CD19 for R/R ALL Acute Lymphoblastic Leukemia With Failed Remission The First Affiliated Hospital of Soochow University|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Phase 1|Phase 2
NCT03271515 Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL Leukemia|Lymphoma Beijing Doing Biomedical Co., Ltd. Phase 1
NCT04215016 Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive Fujian Medical University Phase 1
NCT05149391 A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma B Cell Non-Hodgkin's Lymphoma Peking University|Peking University Cancer Hospital & Institute Phase 1
NCT05535855 UCD19 CAR-T Therapy in Adults With B-ALL and MRD Positivity in CR1 Acute Lymphoid Leukemia|Acute Lymphoblastic Leukemia University of Colorado, Denver Phase 1
NCT05442515 CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|Lymphoma, Non-Hodgkin National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1|Phase 2
NCT03383952 A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia B Cell Leukemia|B Cell Lymphoma Immune Cell, Inc.|Weifang People's Hospital Phase 1
NCT04034446 CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Institute of Hematology & Blood Diseases Hospital|Juventas Cell Therapy Ltd. Early Phase 1
NCT03016377 Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL Acute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative Disorders UNC Lineberger Comprehensive Cancer Center|Bellicum Pharmaceuticals Phase 1|Phase 2
NCT03448393 CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|Lymphoma, Non-Hodgkin National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1
NCT04718883 CD19-targeted CAR-T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma Mantle Cell Lymphoma Shanghai Ming Ju Biotechnology Co., Ltd. Phase 2
NCT05705570 A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia Refractory|B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory|Chronic Lymphocytic Leukemia Recurrent|Chronic Lymphocytic Leukemia Refractory Hospital Israelita Albert Einstein|Miltenyi Biotec, Inc. Phase 1
NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia CD19 Positive|CD20 Positive|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma Jonsson Comprehensive Cancer Center|Parker Institute for Cancer Immunotherapy Phase 1
NCT04626908 Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma Relapsed and Refractory|Lymphoid Hematological Malignancies He Huang|Gracell Biotechnology Ltd.|Zhejiang University Phase 1|Phase 2
NCT05436509 CD19/79b Bi-specific CAR-T Cell Therapy B Cell Malignancies Shenzhen Geno-Immune Medical Institute Phase 1|Phase 2
NCT05114837 Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL Lymphoma Leukemia Masonic Cancer Center, University of Minnesota Phase 1|Phase 2
NCT04037566 CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. Leukemia Lymphocytic Acute (ALL) in Relapse|Leukemia Lymphocytic Acute (All) Refractory|Lymphoma, B-Cell|CD19 Positive Xijing Hospital|Xi'An Yufan Biotechnology Co.,Ltd Phase 1
NCT03085173 A Trial of "Armored" CAR-T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Chronic Lymphocytic Leukemia (CLL)|Relapsed|Refractory Memorial Sloan Kettering Cancer Center|Juno Therapeutics, Inc. Phase 1
NCT04812691 CD19-targeted CAR-T Cells (JWCAR029) for Primary Refractory Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma Shanghai Ming Ju Biotechnology Co., Ltd. Phase 1
NCT05432882 CD19/22 Bi-specific CAR-T Cell Therapy B Cell Malignancies Shenzhen Geno-Immune Medical Institute Phase 1|Phase 2
NCT04089215 CD19-targeted CAR-T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma Lymphoma, Non-Hodgkin|Diffuse Large B Cell Lymphoma|Follicular Lymphoma Shanghai Ming Ju Biotechnology Co., Ltd. Phase 2
NCT05436496 CD19/70 Bi-specific CAR-T Cell Therapy B Cell Malignancies Shenzhen Geno-Immune Medical Institute Phase 1|Phase 2
NCT05206071 Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma Non-hodgkin's Lymphoma Hebei Senlang Biotechnology Inc., Ltd. Not Applicable
NCT04745559 Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy Diffuse Large-Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|High-grade B-cell Lymphoma (HGBCL)|Follicular Lymphoma H. Lee Moffitt Cancer Center and Research Institute Phase 2
NCT04796688 Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies Acute Lymphoblastic Leukemia|Chronic Lymphoblastic Leukemia|B-cell Lymphoma Wuhan Union Hospital, China|Chengdu USino Technology Biology Co., Ltd Phase 1
NCT04697940 Decitabine-primed Tandem CD19/CD20 CAR-T Cells Treatment in r/r B-NHL Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma|Decitabine-primed Tandem CD19/CD20 CAR-T Cells Han weidong|Chinese PLA General Hospital Phase 1|Phase 2
NCT04404660 A Study of CD19 Targeted CAR-T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Autolus Limited Phase 1|Phase 2
NCT05223686 To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. Acute Lymphoblastic Leukemia Hrain Biotechnology Co., Ltd.|Ruijin Hospital Phase 1
NCT04204161 A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood|Refractory B-cell Acute Lymphoblastic Leukemia, Childhood|Relapsed/Refractory B-cell Lymphoma, Childhood Shenzhen BinDeBio Ltd.|Xiangya Hospital of Central South University Phase 1
NCT04512716 Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma B-ALL|DLBCL|B ALL|Dlbcl-Ci|DLBCL Unclassifiable|DLBCL, Nos Genetic Subtypes|DLBCL Activated B-Cell Type|DLBCL Germinal Center B-Cell Type|Diffuse Large B-cell Lymphoma|HGBL|HGBL, Nos Memorial Sloan Kettering Cancer Center|Actinium Pharmaceuticals Early Phase 1
NCT03573700 Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory St. Jude Children's Research Hospital Phase 1|Phase 2
NCT04214392 Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT03287817 CD19/22 CAR-T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|DLBCL Autolus Limited Phase 1|Phase 2
NCT02893189 CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation CD19+ Malignancies: Relapse Post-allogeneic Transplant University College, London Phase 1
NCT05338931 Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma B-cell Non Hodgkin Lymphoma AbClon Phase 1|Phase 2
NCT05105867 CD19 Targeted UCAR-T for CD19+ Refractory/Relapsed B-ALL/NHL B-Cell Leukemia|B Cell Lymphoma 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|Gracell Biotechnology Shanghai Co., Ltd. Early Phase 1
NCT05651178 Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients Central Nervous System Lymphoma Hrain Biotechnology Co., Ltd.|Second Affiliated Hospital of Nanchang University Early Phase 1
NCT03105336 A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Follicular Lymphoma|Marginal Zone Lymphoma|Indolent Non-Hodgkin Lymphoma Kite, A Gilead Company|Gilead Sciences Phase 2
NCT05020678 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Lymphoma, Non-Hodgkin|B-cell Acute Lymphoblastic Leukemia|Large B-cell Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma|Waldenstrom Macroglobulinemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Aggressive Lymphoma|Large-cell Lymphoma Nkarta Inc. Phase 1
NCT04661384 Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma Ependymoma|Glioblastoma|Medulloblastoma|Recurrent Metastatic Malignant Neoplasm in the Leptomeninges City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT04429438 Multi-CAR-T Cells Targeting B Cell Lymphomas B Cell Lymphoma (BCL) Shenzhen Geno-Immune Medical Institute|The Seventh Affiliated Hospital of Sun Yat-sen University|Shenzhen Children's Hospital Phase 1|Phase 2
NCT04231747 A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lymphoma Non-Hodgkin|Agressive Lymphoma|Diffuse-large B-cell Lymphoma (DLBCL) Juno Therapeutics, a Subsidiary of Celgene Phase 1
NCT04430530 4SCAR-T Therapy Post CD19-targeted Immunotherapy CD19 Negative B-cell Malignancies Shenzhen Geno-Immune Medical Institute|ShiJiaZhuang Zhongxi Children Hospital|Shenzhen Children's Hospital|The Seventh Affiliated Hospital of Sun Yat-sen University Phase 1|Phase 2
NCT05420493 Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Non Hodgkin Lymphoma Chongqing Precision Biotech Co., Ltd Phase 1
NCT05091541 A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma B-cell Non-Hodgkin's Lymphoma Nanjing IASO Biotherapeutics Co.,Ltd Phase 1|Phase 2
NCT05054257 CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma Refractory|Non-Hodgkin's Lymphoma, Relapsed Institute of Hematology and Blood Transfusion, Czech Republic Phase 1
NCT05639179 Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL B-cell Acute Lymphoblastic Leukemia|B-ALL 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China Phase 1|Phase 2
NCT05654038 A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies B-Cell Lymphoblastic Leukemia/Lymphoma 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China Phase 1|Phase 2
NCT01840566 High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma Non-Hodgkin's Lymphoma Memorial Sloan Kettering Cancer Center Phase 1
NCT04510051 CAR-T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children Malignant Brain Neoplasm|Recurrent Malignant Brain Neoplasm|Refractory Malignant Brain Neoplasm City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT04049383 CAR-20/19-T Cells in Pediatric and Young Adult Patients With Relapsed/Refractory B Cell ALL Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia With Failed Remission|Acute Lymphoblastic Leukemia Recurrent|Acute Lymphoblastic Leukemia Not Having Achieved Remission|Acute Lymphoblastic Leukemia, Pediatric|Acute Lymphoblastic Leukemia Medical College of Wisconsin|Children's Hospital and Health System Foundation, Wisconsin Phase 1
NCT04483778 B7H3 CAR-T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma|Melanoma Seattle Children's Hospital Phase 1
NCT02735291 Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia Leukemia Sinobioway Cell Therapy Co., Ltd.|The Second Hospital of Anhui Medical University Not Applicable
NCT04416984 Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR-T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Relapsed/Refractory Large B Cell Lymphoma Allogene Therapeutics Phase 1|Phase 2
NCT03939026 Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma Relapsed/Refractory Large B Cell Lymphoma|Relapsed/Refractory Follicular Lymphoma Allogene Therapeutics Phase 1
NCT04016129 CAR-T Immunotherapy Targeting CD19- ALL B-cell Leukemia Shenzhen Geno-Immune Medical Institute Phase 1|Phase 2
NCT04359784 Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy B-Cell Non-Hodgkin Lymphoma Fred Hutchinson Cancer Center|Swedish Orphan Biovitrum Phase 2
NCT03302403 Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors B Cell Lymphoma|B Cell Leukemia|Myeloma|Hepatocellular Carcinoma|Pancreatic Carcinoma|Adenocarcinoma of Esophagogastric Junction Kang YU|CARsgen Therapeutics Co., Ltd.|First Affiliated Hospital of Wenzhou Medical University Not Applicable
NCT05480449 Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) B Cell Acute Lymphoblastic Leukemia (B-ALL)|B Lineage Lymphoblastic Lymphoma Stephan Grupp MD PhD|Children's Hospital of Philadelphia Phase 1|Phase 2
NCT01430390 In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies Acute Lymphocytic Leukemia|Lymphoma Memorial Sloan Kettering Cancer Center Phase 1
NCT05388695 To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors 19 and 22+ B Cell Hematologic Tumors|19 and 20+ B Cell Hematologic Tumors Hebei Senlang Biotechnology Inc., Ltd.|Tongji Hospital Phase 1
NCT04889716 CAR-T Followed by Bispecific Antibodies Large B-cell Lymphoma Abramson Cancer Center of the University of Pennsylvania|Genentech, Inc. Phase 2
NCT04173988 Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia ALL, Childhood B-Cell Children's Hospital of Fudan University Early Phase 1
NCT04778579 Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Acute Lymphoid Leukemia Sara V. Latorre|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Instituto de Salud Carlos III Phase 2
NCT04148430 A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy B Cell ALL|B-Cell Lymphoma|B-cell Non Hodgkin Lymphoma Memorial Sloan Kettering Cancer Center Phase 2
NCT05474885 BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) iCell Gene Therapeutics|iCAR Bio Therapeutics Ltd. China Phase 1
NCT03144583 Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy Leukemia|Lymphoma Sara V. Latorre|Instituto de Salud Carlos III|Institut d'Investigacions Biomèdiques August Pi i Sunyer Phase 1
NCT05281809 Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia B-Cell Lymphoma|B Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Lymphoplasmacytic Lymphoma|Chronic Lymphocytic Leukemia|Transformed Lymphoma John Lister|Lentigen Technology, Inc.|Miltenyi Biotec, Inc.|AHN (Allegheny Health Network) Cancer Institute|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Phase 2
NCT03056339 Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies B-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma M.D. Anderson Cancer Center Phase 1|Phase 2
NCT04557436 TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) B Acute Lymphoblastic Leukemia Great Ormond Street Hospital for Children NHS Foundation Trust|University College, London Phase 1
NCT05472610 Study of Efficacy of BZ019 in Large B-cell Lymphoma Large B-cell Lymphoma Shanghai Mengchao Cancer Hospital|Shanghai Cell Therapy Group Co.,Ltd Phase 2
NCT04236011 BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma Multiple Myeloma Shanghai Changzheng Hospital|Gracell Biotechnology Shanghai Co., Ltd. Early Phase 1
NCT05010564 CAR-T Cell, B-cell Acute Lymphoblastic Leukemia (TriCAR) Leukemia, B-Cell Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute Phase 1
NCT04464200 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma|Chronic Lymphocytic Leukemia|Indolent Non-Hodgkin Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Burkitt's Lymphoma|Primary CNS Lymphoma Memorial Sloan Kettering Cancer Center|Takeda Phase 1
NCT03614858 CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. Leukemia, B-cell Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The First Affiliated Hospital of Soochow University Phase 1|Phase 2
NCT05391490 Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies Blood Cancer University College, London Phase 1
NCT04186520 CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies Non Hodgkin Lymphoma (NHL)|Mantle Cell Lymphoma (MCL)|Chronic Lymphocytic Leukemia (CLL)|Follicular Lymphoma|Marginal Zone Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL) Medical College of Wisconsin Phase 1|Phase 2
NCT03873805 PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT05404048 PD-L1 PET-imaging During CAR T-cell Therapy Large B-cell Lymphoma University Medical Center Groningen Phase 2
NCT05094206 CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies B-cell Non Hodgkin Lymphoma|B-cell Chronic Lymphocytic Leukemia Medical College of Wisconsin|Miltenyi Biomedicine GmbH Phase 1
NCT05627323 CAR-T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma Glioblastoma Multiforme of Brain Chimeric Therapeutics Phase 1
NCT04213469 PD1-CD19-CART in Patients With r/r B-cell Lymphoma B-cell Lymphoma Bioray Laboratories|First Affiliated Hospital of Zhejiang University Not Applicable
NCT03902197 CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients Acute Lymphoblastic Leukemia Xuanwu Hospital, Beijing|Beijing Children's Hospital Phase 2
NCT04440436 Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients NHL Beijing Immunochina Medical Science & Technology Co., Ltd.|Jiangsu Simcere Pharmaceutical Co., Ltd. Phase 1|Phase 2
NCT05412329 Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma Multiple Myeloma Shanghai Changzheng Hospital|Gracell Biotechnology Shanghai Co., Ltd. Phase 1
NCT03896854 CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Phase 1|Phase 2
NCT04107285 Looking at Brain Changes in People With Lymphoma Receiving CAR-T Therapy Lymphoma Receiving CAR-T Therapy Memorial Sloan Kettering Cancer Center undefined
NCT03389035 Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT Acute Lymphoblastic Leukemia, in Relapse Fondazione Matilde Tettamanti Menotti De Marchi Onlus Phase 1|Phase 2
NCT04792489 DALY 2.0 USA/ MB-CART2019.1 for DLBCL DLBCL Miltenyi Biomedicine GmbH Phase 2
NCT05672173 Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Transformed Chronic Lymphocytic Leukemia|Richter Syndrome City of Hope Medical Center|National Cancer Institute (NCI) Phase 2
NCT03960840 CD19-specific CAR-T Cells in CLL/SLL, DLBCL and ALL Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia Novartis Pharmaceuticals|Novartis Phase 1
NCT03870945 Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) B-cell Non Hodgkin Lymphoma Miltenyi Biomedicine GmbH|ICON plc Phase 1|Phase 2
NCT03244306 A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma Leukemia Seattle Children's Hospital Phase 1
NCT04226989 A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma He Huang|Nanjing Bioheng Biotech Co., Ltd.|Zhejiang University Early Phase 1
NCT04989803 Study Evaluating the Safety and Efficacy of KITE-363 in Participants With Relapsed and/or Refractory B-cell Lymphoma Relapsed and/or Refractory B-cell Lymphoma Kite, A Gilead Company|Gilead Sciences Phase 1
NCT04119024 Gene Modified Immune Cells (IL13Ralpha2 CAR-T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma Clinical Stage IV Cutaneous Melanoma AJCC v8|IL13RA2 Positive|Metastatic Melanoma|Cutaneous Melanoma, Stage III|Cutaneous Melanoma, Stage IV Jonsson Comprehensive Cancer Center|City of Hope National Medical Center Phase 1
NCT05641428 Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL NHL|DLBCL - Diffuse Large B Cell Lymphoma University Medical Center Groningen|Stichting Hemato-Oncologie voor Volwassenen Nederland Phase 2
NCT04290000 Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies Lymphoma and Acute Lymphoblastic Leukemia University Hospital, Montpellier undefined
NCT05312801 Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma Lymphoma, Non-Hodgkin Lymphoma, B-Cell Luminary Therapeutics|Case Comprehensive Cancer Center Phase 1
NCT04003649 IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM Recurrent Glioblastoma|Refractory Glioblastoma City of Hope Medical Center|National Cancer Institute (NCI) Phase 1
NCT05292898 A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia Acute Lymphocytic Leukemia Institute of Hematology & Blood Diseases Hospital|Nanjing Legend Biotech Co. Phase 1
NCT05130489 CAR-T Cell Therapy Related Cardiovascular Outcomes Cardiovascular Diseases|B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Diffuse Large B Cell Lymphoma|Cardiotoxicity|Cardiovascular Complication University College London Hospitals undefined
NCT05381181 Safety and Efficacy Evaluation of Next-generation CD19-UCART Acute Lymphoblastic Leukemia|Non Hodgkin Lymphoma Bioray Laboratories|The First Affiliated Hospital of Zhengzhou University Phase 1
NCT05631912 TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL Non-hodgkin Lymphoma,B Cell Chinese PLA General Hospital Phase 1|Phase 2
NCT02208362 Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma|Refractory Glioblastoma|Refractory Malignant Glioma|Refractory WHO Grade II Glioma|Refractory WHO Grade III Glioma City of Hope Medical Center|National Cancer Institute (NCI)|Food and Drug Administration (FDA) Phase 1
NCT04340167 Study of Anti-CD22 CAR-T Cells Treating Leukemia Children Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia Beijing Boren Hospital Phase 2
NCT02631044 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle-cell Lymphoma|Primary Mediastinal B-cell Lymphoma Juno Therapeutics, a Subsidiary of Celgene Phase 1
NCT03383965 CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma Immune Cell, Inc.|Weifang People's Hospital Phase 1
NCT04684563 huCART19-IL18 in NHL/CLL Patients Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma University of Pennsylvania Phase 1
NCT01860937 T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Relapsed B-Cell Acute Lymphoblastic Leukemia Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital Phase 1
NCT04276870 Orphan Indications for CD19 Redirected Autologous T Cells Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL|Infants With Very High Risk KMT2A B-ALL|Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation Stephan Grupp MD PhD|University of Pennsylvania|Children's Hospital of Philadelphia Phase 2
NCT04595162 A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL B-cell Acute Lymphoblastic Leukemia Peking University Third Hospital|Gracell Biotechnology Ltd. Phase 1
NCT05077527 Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma AIDS-Related Diffuse Large B-cell Lymphoma|AIDS-Related Non-Hodgkin Lymphoma|HIV Infection|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3b Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma AIDS Malignancy Consortium|National Cancer Institute (NCI) Phase 1
NCT03620058 CART22 Alone or in Combination With huCART19 for ALL Chemotherapy Resistant Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia University of Pennsylvania Phase 1
NCT03196414 Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma Multiple Myeloma The First Affiliated Hospital of Soochow University Phase 1|Phase 2
NCT04419909 Retreatment With CTL019/CTL119 Lymphoma, B-Cell University of Pennsylvania Phase 1
NCT03792633 Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL Acute Lymphoid Leukemia University of Pennsylvania|Children's Hospital of Philadelphia Phase 2
NCT04935580 Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients Multiple Myeloma Shanghai Changzheng Hospital|Gracell Biotechnology Shanghai Co., Ltd. Phase 1|Phase 2
NCT00466531 Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Leukemia Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) Phase 1|Phase 2
NCT05514327 A Study of Ultra-fraction Radiotherapy Bridging CAR-T in R/R DLBCL Diffuse Large B Cell Lymphoma|CAR-T|Radiotherapy|Bridging Therapy Peking Union Medical College Hospital Not Applicable
NCT05667506 A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) B-cell Acute Lymphoblastic Leukemia Juventas Cell Therapy Ltd. Phase 1|Phase 2
NCT05460533 A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Lymphoma (B-ALL) B-cell Acute Lymphoblastic Leukemia Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals Phase 2
NCT04844866 Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients Diffuse Large B-cell Lymphoma Miltenyi Biomedicine GmbH|ICON plc Phase 2
NCT03226704 Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing Leukemia|Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Non-Hodgkin's Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) undefined
NCT02735083 A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19 Advanced Lymphoid Leukemia Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier Phase 1
NCT05318963 Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory Qiu Lugui|Nanjing Legend Biotech Co.|Institute of Hematology & Blood Diseases Hospital Phase 1
NCT04827745 Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL Mixed Phenotype Acute Leukemia (MPAL)|Measurable Residual Disease (MRD) University of Maryland, Baltimore Phase 2
NCT05643742 A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies B-cell Lymphoma|Non-Hodgkin Lymphoma|B-cell Malignancy|Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Large B-cell Lymphoma CRISPR Therapeutics AG|CRISPR Therapeutics Phase 1|Phase 2
NCT05310591 Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence B Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse Assistance Publique - Hôpitaux de de Paris Phase 1|Phase 2
NCT04014894 ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma Leukemia|Lymphoma Wuhan Union Hospital, China|Eureka(Beijing) Biotechnology Co., Ltd. Phase 1

References

  1. Cappell, Kathryn M., and James N. Kochenderfer. "Long-term outcomes following CAR-T cell therapy: what we know so far." Nature Reviews Clinical Oncology (2023): 1-13.
  2. Lillis, A. M., et al. "Regulation of B cell receptor signaling by CD19." Journal of Leukocyte Biology, vol. 102, no. 4, 2017, pp. 961-970.
  3. He, Changhao, et al. "CD19 CAR antigen engagement mechanisms and affinity tuning." Science Immunology 8.81 (2023): eadf1426.
  4. Wang, Kemeng, Guoqing Wei, and Delong Liu. "CD19: a biomarker for B cell development, lymphoma diagnosis and therapy." Experimental hematology & oncology 1.1 (2012): 1-7.
  5. Globerson Levin, Anat, et al. "CAR T cells: Building on the CD19 paradigm." European journal of immunology 51.9 (2021): 2151-2163.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.